Pall is looking to extend its capabilities inthe more than $1 billion biopharmaceuticals process monitoring market and inthe protein research market, and it expects to see gains in both areas with the addition of ForteBio'slabel-free protein analysis instruments. Calling those products "an ideal complement to Pall's existingmicrobiological monitoring platforms," Pall notes that ForteBio's portfolio of analyticalsolutions allows researchers to measure proteins in real time without the aidof fluorescent, radio or calorimetric labels or markers that can contaminatesamples, thus enabling easier, faster and better characterizationof drug candidates—all with an eye toward improving process development and speeding timeto market.
"Demand for label-free proteinanalysis continues to intensify and through the merger we now can bring theadvantages of ForteBio systems to a wider range of customers," notes Dr. Joseph D.Keegan, ForteBio's CEO and president, adding that Pall's strong global sales channel willextend the reach of ForteBio instruments "and better position us to capitalizeon opportunities in emerging regions in Europe and Asia."
ForteBio's original Octet family of products isbased on the company's proprietary BioLayer Interferometry (BLI) technology. Itincorporates disposable optical Dip and Read biosensors that measure multipleinteractions in parallel, without the use of detection agents. Forsingle-sample analysis, ForteBio recently launched its BLItz platform. According to the companies, the newplatform "revolutionizes" the use of label-free protein analysis by making itmore accessible and cost-effective for individual bench scientists andresearchers.
ForteBio's original Octet family of products isbased on the company's proprietary BioLayer Interferometry (BLI) technology. Itincorporates disposable optical Dip and Read biosensors that measure multipleinteractions in parallel, without the use of detection agents. Forsingle-sample analysis, ForteBio recently launched its BLItz platform. According to the companies, the newplatform "revolutionizes" the use of label-free protein analysis by making itmore accessible and cost-effective for individual bench scientists andresearchers.
Continue reading below...
WebinarsAccelerating rare disease clinical trials
Explore how a rare kidney disease trial achieved faster patient enrollment with data-informed strategies and collaborative partnerships.
Read More"We are thrilled about the acquisition of ForteBioand the added value it enables Pall to bring to customers," says LarryKingsley, Pall's CEO and president. "BioPharmaceuticals continues to be theengine of our life sciences business and an important long-term growthaccelerator. The addition of ForteBio's platforms into our business reinforcesPall's commitment to helping customers get their life-changing products tomarket safely and on time."
Upon closing, ForteBio will become a wholly-ownedsubsidiary of Pall Corp. In the short term, the impact to Pall's results ofoperations will be immaterial, according to Kingsley.
